Global biopharmaceutical company AbbVie has received priority review from the Japanese Ministry of Health, Labour and Welfare for Glecaprevir/Pibrentasvir, its drug for the treatment of chronic hepatitis C.
The U.S. Food and Drug Administration approved AbbVie’s IMBRUVICA for treatment of relapsed/refractory marginal zone lymphoma in patients who require systemic therapy and have received at least one prior anti-CD 20-based therapy.
The AbbVie investigational, pan-genotypic, ribavirin-free regimen of glecaprevir (ABT-493)/Pibrentasvir (ABT-530) (G/P) achieved high SVR12 rates after eight weeks of treatment in Japanese patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infections without cirrhosis.
For stepping up during a 2015 natural disaster to partner with the International Medical Corps in Nepal, Abbvie recently received a Global Citizen Award, honoring its humanitarian actions in the wake of a destructive earthquake.
Leaders at AbbVie, a worldwide biopharmaceutical company, recently announced that it has launched its phase-three clinical trial concerning venetoclax, which is designed to treat patients who have relapsed or refractory multiple myeloma.
AbbVie, a worldwide biopharmaceutical company, recently announced that it has gained approval from the U.S. Food and Drug Administration (FDA) to use its once-daily Viekira XR formula to treat genotype 1 chronic hepatitis C.
Boehringer Ingelheim recently announced that its phase-two study results show that the company’s new treatment, IL-23 inhibitor risankizumab, induces remission in patients who have moderate-to-severe Crohn’s disease.
AbbVie, a worldwide biopharmaceutical company, recently announced that officials at the European Commission (EC) have approved Imbruvica to be used as a first-line treatment option for chronic lymphocytic leukemia (CLL).
AbbVie, a worldwide, research-focused biopharmaceutical company, recently announced that it will have representatives giving presentations that will be transmitted via webcast from the Jefferies 2016 Healthcare Conference on June 8.
A new toolkit from the Agency for Healthcare Research and Quality (AHRQ) helps health care organizations as well as providers better communicate with their patients and families if something wrong occurs during patient care.
The FDA recently expanded the label for Imbruvica (ibrutinib) to include data that show the overall survival increases for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).